Kelso Pharma, the growing UK-based specialty pharmaceuticals business, has appointed life sciences leader, Dr. Bee Koen Low, as its first Chief Operating Officer.
With over 20 years’ experience in the pharmaceutical industry, Bee brings extensive scientific expertise and understanding of the sector to the role, including in the key areas of: M&A due diligence and integrations, technology transfers; supply chain strategy; and pipeline development, as Kelso Pharma gears up for further growth in what has already been a busy 2025 for the business. Bee has spent over 10 years at ADVANZ PHARMA in a number of leadership positions, focusing on project management, technical operations and operations diligence and integration. She was heavily involved in merger and acquisition, working with business partners across the globe. Prior to that, Bee was at GW Pharmaceuticals (now part of Jazz Pharmaceuticals), where she was instrumental in advancing product pipeline development, resulting in novel products that are now successfully marketed in the UK and US.
Kelso Pharma is focused on bringing innovative, value-added, specialty medicines to international healthcare markets, providing products that improve the lives of patients in a cost-effective and ethical manner. The company is growing through a blend of company and product acquisitions, partnerships and organic growth internationally.
Bee’s appointment follows several important announcements from the business in 2025 so far, including the acquisition of UK pharma business, ALTURiX, the appointment of Giovanni Mauri as General Manager of Velit Biopharma in Italy and securing £140m of acquisition funding to accelerate its growth plans, with the appointment of former ADVANZ PHARMA CEO, Graeme Duncan, as Non-Executive Director, strengthening the leadership team.
Commenting on the appointment, Kelso Pharma CEO, Dr. Tom Stratford, said:
“As Kelso Pharma continues to grow in the UK and across Europe, it’s vital we build a leadership team that can take us to the next level. Bee joining us as Chief Operating Officer is a statement of intent of our ambition and determination to organically grow the business to support as many patients as possible.
“I’m looking forward to working with Bee as we build a truly pan European pharma business.”
Dr. Bee Koen Low, added:
“It’s an incredibly exciting time to be joining the Kelso Pharma team. The growth the business has experienced in the past few years has been fantastic and I’m looking forward to playing a key role in supporting our team continue to grow the business across Europe, as we aim to support as many patients as we can.”
If you would like to discuss your communications needs and some of the services we offer including public relations, media relations, crisis communications, digital strategy and others, you can reach our friendly team on +44 (0) 141 548 5191 or send us an email.
Find out more about what we do on the Services page and explore our Work.
